Company news

Devonian Health Group, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Devonian Health Group Receives Health Canada Authorization to Evaluate Novel Thykamine(TM) Formulation for Prevention of Radiation-Induced Skin Injury in Breast Cancer Patients

October 20, 2026

Devonian Health Group Provides Update on its Planned NYSE American Listing

October 16, 2026

Devonian Health Group Inc. Anticipates to Commence Trading on the NYSE American

September 11, 2026

Devonian Health Group Strengthens Thykamine™ Manufacturing Platform with Validated Chemical-Composition Fingerprinting and Biological Potency Assay

September 1, 2026

Devonian Health Group Anticipates to Commence Trading on the NYSE American

August 18, 2026

Devonian Health Group Announces Proposed Listing on the NYSE American with Concurrent Underwritten Public Offering

July 26, 2026

Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Years

July 21, 2026

Devonian Health Group Reports Financial and Operating Results of its Three and Nine Months Ended April 30, 2026

June 29, 2026

Devonian Health Group Inc. Reports Financial and Operating Results of its Three and Six Months Ended January 31, 2026

March 25, 2026

Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine(TM), with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects

February 19, 2026

Devonian Advances Thykamine(TM) Patent Strategy with Proprietary Fingerprint and Robust Manufacturing Controls

February 17, 2026

Devonian reports additional molecular data from MASH liver study

February 12, 2026

Devonian reports positive results in pulmonary fibrosis study

February 10, 2026

Devonian appoints Dennis Turpin as Chief Financial Officer and provides updates on stock options grant

February 2, 2026

Devonian announces share consolidation in further preparation for potential U.S. listing

January 20, 2026

Devonian Health Group Announces Grant of Stock Options

December 19, 2025

Devonian Health Group Reports Financial Results of its First Quarter Ended on October 31, 2025 and Provides Corporate Update

December 12, 2025

Devonian Health Group Announces Publication of Landmark Study Highlighting Thykamine™ as a Promising New Anti-Inflammatory Agent

December 4, 2025

Devonian Health Group Reports its Fourth Quarter and Annual 2025 Financial Results and Appointment of a New Board Member

November 26, 2025

Devonian Health Group Inc. announces its participation to the ThinkEquity Conference in New York and closing of a Non-Brokered Private Placement of Units

October 21, 2025

Devonian Provides Corporate Update and Additional Information Regarding its Previously Announced Private Placement

August 22, 2025

Devonian Announces Closing of a Private Placement of Units

August 7, 2025

Devonian Health Group Reports Third Quarter 2025 Financial Results

June 26, 2025

Devonian Appoints New Officers and Announces Grant of Stock Options

June 9, 2025

Devonian Health Group Announces Reinstatement of Quotation on the TSXV

April 28, 2025

Devonian Health Group Reports Second Quarter 2025 Financial Results

April 15, 2025

Devonian Health Group Reports Cease Trade Order

April 14, 2025

Devonian Reports Delay of Financial Reporting

April 1, 2025

Devonian Reports Results of its Annual General and Special Meeting of Shareholders

March 24, 2025

Devonian Announces the Filing of a New Patent Application Relating to the Use of Thykamine™ as an Antifibrotic Agent

February 19, 2025

Devonian Announces Positive in Vivo Results of Thykamine™ on Gene Expression Associated With Fibrosis

February 18, 2025

Devonian Announces the Filing of a New Provisional Patent Application Relating to the Use of Thykamine(TM) for Treating Metabolic Dysfunction-Associated Steatohepatitis (MASH)

February 13, 2025

Devonian Reports Positive Results in MASH Liver Study

February 13, 2025

Devonian Reports Distribution Agreement Termination

February 7, 2025

InvestmentPitch Media Invites Investors to the GCFF Conference in Toronto on September 30, 2017 - Video Hosted on InvestmentPitch.com

September 28, 2017

Decks

The 5 newest of 9 decks. Every deck is listed under its year.